Population Health November 6, 2023
America’s Cholesterol Awareness Problem November 6, 2023
The prevalence of US adults with high LDL cholesterol levels, and the prevalence of adults who are unaware of their high LDL-C are both declining. However, these improvements aren't happening nearly fast enough - especially given our expanding cholesterol treatment options.
Pharmaceuticals November 2, 2023
Chinese Medicine Tongxinluo Improves STEMI Outcomes, Sparks Debates November 2, 2023
Could the next major heart attack treatment come from a traditional Chinese medicine? A new JAMA study suggests that might be more realistic than many of us think, after showing that the Chinese medicine Tongxinluo significantly improves outcomes among patients with acute ST-segment elevation myocardial infarction (STEMI).
Surgeries & Interventions October 30, 2023
Promising Drug-Coated Balloon Results for In-Stent Restenosis October 30, 2023
The United States has been way behind other nations in using drug-coated balloons to treat coronary in-stent restenosis, but that might change soon thanks to the results from the AGENT IDE Trial.
Artificial Intelligence October 26, 2023
Healthcare AI Clearances Boom, While Cardiology AI Stalls October 26, 2023
The FDA’s annual Healthcare AI Report had medtech social media buzzing this week, showing that an impressive 692 AI-enabled devices have landed FDA clearance as of July 2023, while revealing an apparent slowdown in cardiovascular AI approvals.
Pharmaceuticals October 23, 2023
Pemvidutide’s Weight Loss and CVD Evidence October 23, 2023
Interim Phase 2 results from the MOMENTUM trial show that Altimmune’s pemvidutide drove significant weight loss and improved key cardiovascular metrics.
Pharmaceuticals October 19, 2023
Novo Nordisk Expands CV Pipeline with Ocedurenone Acquisition October 19, 2023
Novo Nordisk took advantage of its semaglutide windfall, expanding its cardiovascular drug pipeline by acquiring ocedurenone from KBP Biosciences for $1.3 billion.
Cardiology October 13, 2023
GE and Mediport’s One-Stop Cardiology Clinic October 13, 2023
With a direct target on streamlining the cardiovascular care pathway, GE HealthCare and Belgian healthcare organization Mediport announced the launch of the first One-Stop Clinic for Cardiology.
Pharmaceuticals October 12, 2023
Semaglutide Adds to Cardiovascular Resume October 12, 2023
Semaglutide continued to add to its cardiovascular resume, with two new studies highlighting its ability to improve heart failure symptoms and cardiorenal outcomes.
Value-Based Care October 9, 2023
CVAUSA and InnovaCare’s Value-Based Alliance October 9, 2023
A new Cardiovascular Associates of America and InnovaCare Health is aiming to create a new model for cardiology + primary care VBC delivery.
Cardiology October 5, 2023
MedAxiom on the State of Cardiovascular Providers October 5, 2023
MedAxiom just released its 11th annual Compensation and Production Report, revealing general stability in 2022 after years of significant change.
Surgeries & Interventions October 2, 2023
Adena Health Pauses Cardiac Surgeries Amid Mounting Controversies October 2, 2023
Ohio’s Adena Health System has temporarily stopped performing heart surgeries, after months of growing scrutiny and some troubling deaths.
Population Health September 28, 2023
The CDC’s Heavy Obesity Update September 28, 2023
Obesity is easily among the leading cardiovascular disease risk factors, and its overall impact on public cardiovascular health could be rising faster than many of us might imagine. In just 10 years, the U.S. went from having zero states with an obesity prevalence above 35% to a whopping 22 states in 2022.
Cardiology September 25, 2023
Cardiovascular Societies Seek A Board of Their Own September 25, 2023
After months of growing cardiologist backlash against the ABIM’s Maintenance of Certification program, four leading cardiovascular societies collectively announced plans to create a new cardiology board to replace it.
Pharmaceuticals September 21, 2023
Abelacimab Significantly Reduces Bleeding September 21, 2023
Anthos Therapeutics celebrated its Phase II results showing that its Factor XI inhibitor abelacimab significantly reduced bleeding among AFib patients compared to rivaroxaban.
Cardiology September 18, 2023
Cardiology in 2073 September 18, 2023
Most of cardiology today was unknown or in its very early stages fifty years ago, and this forecast suggests that “cardiology will change as much in the next 50 years.”
Pharmaceuticals September 14, 2023
Lorundrostat’s Safe and Effective Blood Pressure Control September 14, 2023
An aldosterone inhibitor called lorundrostat took a step towards becoming the first new antihypertensive agent class in nearly 15 years, after safely and effectively treating patients with uncontrolled blood pressure in a Phase II trial.
Pharmaceuticals September 11, 2023
Zilebesiran Phase 2 Results Show Long-Lasting Blood Pressure Impact September 11, 2023
Zilebesiran’s path towards becoming the first long-lasting antihypertensive medication gained more momentum, with new topline Phase 2 results demonstrating that a single injection significantly reduces systolic blood pressure through six months.
Artificial Intelligence September 7, 2023
The State of Cardiology AI September 7, 2023
The cardiology AI segment is showing more clinical and commercial promise than just about any AI segment in healthcare outside of radiology, and its rapid evolution is worth our attention. Because of that, we’re taking a deep dive into the state of cardiology AI and the key trends driving its growth.
Electrophysiology August 31, 2023
Most Subclinical AF Patients Better Off Without Anticoagulants August 31, 2023
The growing number of people walking around with implantable and wearable cardiac monitoring devices will undoubtedly lead to far more subclinical AFib detections. But the NOAH-AFNET 6 trial provided some much needed reassurance that many of these patients would be better off without anticoagulants.
